Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health expanded its board of directors and appointed Michael Smith as a new independent director, effective February 18, 2026. He was also named to the audit committee and the nominating and corporate governance committee, and is designated an “audit committee financial expert” under SEC and NYSE rules.
Smith brings more than three decades of experience in insurance and financial services, including senior roles at Voya Financial and Lincoln Financial, and currently serves as Executive Chairman of Talcott Financial Group. Teladoc Health also announced it will release fourth quarter 2025 results on February 25, 2026, followed by a conference call at 5:00 p.m. ET.
Teladoc Health, Inc. reported that long-serving director Thomas G. McKinley notified the company on February 8, 2026 of his intention to retire from the Board, effective February 20, 2026. The company states that Mr. McKinley is retiring for personal reasons and not due to any disagreement with the company on any matter.
Teladoc Health’s Chief Accounting Officer reported routine equity transactions in company stock. On 01/02/2026, restricted stock units converted into 2,083 shares of Teladoc Health common stock on a one-for-one basis. On 01/05/2026, the officer sold 758 shares at $7.145 per share to cover tax withholding obligations related to the vesting of restricted stock units.
After these transactions, the officer held 6,686 shares of Teladoc Health common stock directly and 14,584 restricted stock units. The filing notes that an earlier grant of 25,000 restricted stock units from October 1, 2024 vests one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health director reports RSU conversion into common stock. On 12/19/2025, the reporting person converted 1,016 restricted stock units into an equal number of Teladoc Health common shares, increasing directly held common stock to 9,145 shares. A related derivative line shows 1,016 restricted stock units being settled for 1,016 common shares at an exercise price of $0, leaving 3,050 restricted stock units beneficially owned.
The filing notes that these restricted stock units were originally granted on September 20, 2023, in an award of 12,195 units that vest one‑third on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health, Inc. disclosed that board member J. Eric Evans plans to retire from its Board of Directors. He informed the company on December 11, 2025 that he will not stand for reelection at Teladoc Health’s 2026 Annual Meeting of Stockholders and will retire from the Board at the conclusion of that meeting.
Mr. Evans has served as a director since 2023. The company notes that he is retiring for personal reasons and that his decision is not due to any disagreement with Teladoc Health on any matter.
Teladoc Health, Inc. reported that on December 9, 2025 it amended its 2023 Employment Inducement Incentive Award Plan. The amendment increases the number of shares of common stock reserved for issuance under the 2023 Inducement Plan by 1,780,000 shares, bringing the total reserve to 7,280,000 shares of common stock.
This plan is used to grant equity awards to new employees as inducement for joining the company. Teladoc notes that the 2023 Inducement Plan was adopted by the Board without stockholder approval in reliance on NYSE Rule 303A.08, which permits certain inducement awards without a shareholder vote.
Teladoc Health’s chief executive officer reported new stock activity in a Form 4 filing. On December 10, 2025, 39,160 restricted stock units vested and converted into the same number of shares of Teladoc common stock. On December 11, 2025, the CEO sold 17,138 shares of common stock at an average price of $7.6343 per share to cover tax withholding obligations tied to this vesting.
After these transactions, the CEO directly owned 201,036 shares of Teladoc common stock and held 234,963 restricted stock units. The restricted stock units referenced stem from a grant of 469,924 units made on June 10, 2024, which vests one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments.
Teladoc Health insider plans to sell recently vested shares. A holder has filed notice to sell 17,138 shares of Teladoc Health common stock through Fidelity Brokerage Services on or about 12/11/2025, with an aggregate market value of $130,836.63. The filing notes that 177,473,405 Teladoc shares were outstanding, giving context for the size of this planned sale.
The 17,138 shares to be sold were acquired on 12/10/2025 via restricted stock vesting as compensation from the issuer. The same seller, Charles Divita, previously sold 16,787 Teladoc common shares on 09/11/2025 for gross proceeds of $127,435.15. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about Teladoc’s operations.
Teladoc Health, Inc. insider equity activity: A company officer, the President of BetterHelp, reported multiple stock transactions in early December 2025. On December 1, 2025, the officer exercised restricted stock units that converted on a one-for-one basis into 5,491 shares of Teladoc common stock and an additional 1,042 shares, both at an exercise price of $0, reflecting vesting of prior equity awards.
On December 2, 2025, the officer sold 2,324 shares of common stock at $7.488 per share to cover tax withholding obligations related to the vesting. On December 3, 2025, a further 4,209 shares were sold at $7.48 per share pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024 and amended on November 27, 2024. Following these transactions, the form shows remaining holdings in restricted stock units, including 21,966 and 5,210 units from prior grants that continue to vest over time.
Teladoc Health’s chief legal officer and secretary reported routine stock activity related to vesting of prior equity awards. On December 1, 2025, 1,505 performance stock units and two blocks of restricted stock units (4,418 and 5,350 units) converted on a one-for-one basis into shares of Teladoc common stock. On December 2, 2025, 5,720 common shares were sold at $7.488 per share to satisfy tax withholding obligations tied to these vesting events. After these transactions, the officer directly owns 80,732 shares of common stock and continues to hold derivative awards, including performance and restricted stock units scheduled to vest over time.